Skip to main content
66°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Acadia Pharmaceuticals Inc.
< Previous
1
2
3
4
Next >
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
March 13, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
March 05, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
March 03, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
February 27, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
February 26, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 14, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
February 12, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
January 14, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
December 11, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
December 09, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
November 26, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
November 21, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 15, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
November 06, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
November 05, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
October 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
October 16, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 26, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
September 23, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
August 28, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Ryan Reynolds Announces More to Parkinson’s® Campaign
August 14, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
August 06, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
July 24, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
July 18, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.